Aptamer-functionalized liposomes for targeted cancer therapy
- PMID: 30763718
- DOI: 10.1016/j.canlet.2019.01.045
Aptamer-functionalized liposomes for targeted cancer therapy
Abstract
Accumulation of chemotherapeutic agents in the tumor tissue while reducing adverse effects and drug resistance are among the major goals in cancer therapy. Among nanocarriers, liposomes have been found to be more effective in the passive targeting of cancer cells. A promising recent development in targeted drug delivery is the use of aptamer-functionalized liposomes for cancer therapy. Aptamer-targeted liposomes have enhanced uptake in tumor cells as shown in vitro and in vivo. Here, we discuss the aptamer-functionalized liposome platforms and review functionalization approaches as well as the factors affecting antitumor efficiency of aptamer-targeted liposomal systems. Finally, we provide a comprehensive overview of aptamer-targeted liposomes based on the molecular targets on the surface of cancer cells.
Keywords: Aptamer; Chemotherapy; Drug delivery; Liposome.
Copyright © 2019 Elsevier B.V. All rights reserved.
Similar articles
-
RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo.J Control Release. 2014 Dec 28;196:234-42. doi: 10.1016/j.jconrel.2014.10.018. Epub 2014 Oct 24. J Control Release. 2014. PMID: 25450401
-
Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.Colloids Surf B Biointerfaces. 2016 Mar 1;139:228-36. doi: 10.1016/j.colsurfb.2015.12.009. Epub 2015 Dec 15. Colloids Surf B Biointerfaces. 2016. PMID: 26722819
-
Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer.Eur J Pharm Biopharm. 2017 May;114:108-118. doi: 10.1016/j.ejpb.2017.01.011. Epub 2017 Jan 25. Eur J Pharm Biopharm. 2017. PMID: 28131717 Free PMC article.
-
Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities.J Control Release. 2018 May 10;277:1-13. doi: 10.1016/j.jconrel.2018.02.040. Epub 2018 Mar 1. J Control Release. 2018. PMID: 29501721 Review.
-
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.Eur J Pharm Biopharm. 2015 Jun;93:52-79. doi: 10.1016/j.ejpb.2015.03.018. Epub 2015 Mar 23. Eur J Pharm Biopharm. 2015. PMID: 25813885 Review.
Cited by
-
Lipid-Based Nanotechnology: Liposome.Pharmaceutics. 2023 Dec 26;16(1):34. doi: 10.3390/pharmaceutics16010034. Pharmaceutics. 2023. PMID: 38258045 Free PMC article. Review.
-
Synergistic vesicle-vector systems for targeted delivery.J Nanobiotechnology. 2024 Jan 3;22(1):6. doi: 10.1186/s12951-023-02275-6. J Nanobiotechnology. 2024. PMID: 38167116 Free PMC article. Review.
-
Natural and synthetic nanovectors for cancer therapy.Nanotheranostics. 2023 Mar 5;7(3):236-257. doi: 10.7150/ntno.77564. eCollection 2023. Nanotheranostics. 2023. PMID: 37064613 Free PMC article. Review.
-
Advances in nanomaterials for the diagnosis and treatment of head and neck cancers: A review.Bioact Mater. 2022 Sep 2;25:430-444. doi: 10.1016/j.bioactmat.2022.08.010. eCollection 2023 Jul. Bioact Mater. 2022. PMID: 37056270 Free PMC article.
-
[99mTc]Technetium-Labeled Niosomes: Radiolabeling, Quality Control, and In Vitro Evaluation.ACS Omega. 2023 Feb 8;8(7):6279-6288. doi: 10.1021/acsomega.2c06179. eCollection 2023 Feb 21. ACS Omega. 2023. PMID: 36844604 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
